MediWound (NASDAQ:MDWD) COO Shmuel Hess Sells 1,865 Shares

MediWound Ltd. (NASDAQ:MDWD) COO Shmuel Hess sold 1,865 shares of MediWound stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $13.00, for a total value of $24,245.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Shmuel Hess also recently made the following trade(s):

• On Thursday, August 27th, Shmuel Hess sold 3,958 shares of MediWound stock. The stock was sold at an average price of $12.92, for a total value of $51,137.36.

MediWound Stock Down 4.4%

MediWound stock traded down $0.58 during mid-day trading on Friday, hitting $12.66. 165,534 shares of the company were exchanged, compared to its average volume of 92,786. MediWound Ltd. has a 1-year low of $12.52 and a 1-year high of $20.30. The business has a fifty day moving average of $14.19 and a 200 day moving average of $15.66. The company has a market capitalization of $162.71 million, a PE ratio of -7.03 and a beta of 0.15.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The firm had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%. Research analysts expect that MediWound Ltd. will post -2.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Kotler Kevin bought a new position in shares of MediWound during the fourth quarter worth $6,225,000. Sphera Funds Management LTD. increased its stake in MediWound by 24.3% during the 4th quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock worth $4,252,000 after purchasing an additional 45,077 shares in the last quarter. Silverberg Bernstein Capital Management LLC increased its stake in MediWound by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company’s stock worth $3,222,000 after purchasing an additional 16,081 shares in the last quarter. Millennium Management LLC lifted its stake in MediWound by 355.6% in the third quarter. Millennium Management LLC now owns 175,383 shares of the biopharmaceutical company’s stock valued at $3,160,000 after buying an additional 136,884 shares in the last quarter. Finally, UBS Group AG boosted its holdings in shares of MediWound by 90.1% in the fourth quarter. UBS Group AG now owns 145,057 shares of the biopharmaceutical company’s stock valued at $2,678,000 after buying an additional 68,756 shares during the period. Institutional investors own 46.83% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on MDWD shares. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. Oppenheimer restated an “outperform” rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Wall Street Zen lowered MediWound from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of MediWound in a research report on Thursday, May 28th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, MediWound currently has an average rating of “Hold” and an average target price of $33.00.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.